Royalty Pharma plc (RPRX) Investment Research Dashboard
About Royalty Pharma plc (RPRX) stock analysis
Get live RPRX stock price $58.73, comprehensive Royalty Pharma plc stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time RPRX stock data and investment insights.
Loading chart data...
Royalty Pharma plc (RPRX) Overview
Royalty Pharma plc (RPRX) is a publicly traded company in the Healthcare sector , specifically within the Medical - Pharmaceuticals industry . As of the latest trading session, RPRX trades at $58.73 with a market capitalization of 25.26B . Over the past 52 weeks, RPRX has traded between $34.08 and $59.72 , with the current price positioned at approximately 96% of this range . The stock currentl...
Key Takeaways
- Operates in the Healthcare sector (Medical - Pharmaceuticals)
- Market cap: 25.26B
- Current price: $58.73
- 52-week range: $34.08 - $59.72
- P/E ratio: 11.58
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...
Company Information
- CEO
- Pablo Legorreta
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 100
Contact Information
- Address
- 110 East 59th Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Listed on major US exchange (NASDAQ) providing liquidity and transparency
✓ Valuation metrics suggest potential value opportunity (P/E: 11.6)
✓ Lower volatility stock (Beta: 0.42) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Royalty Pharma plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Royalty Pharma plc
- ⚠Investors should consider how Royalty Pharma plc fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
25.26B
P/E Ratio (TTM)
11.58
Beta
0.42
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare RPRX with peer companies:
- Price
- $55.81+0.79% (1D)
- Market cap
- 14.03B
- Price
- $24.87+1.14% (1D)
- Market cap
- 13.36B
- Price
- $28.80-0.24% (1D)
- Market cap
- 17.68B
- Price
- $76.01+0.00% (1D)
- Market cap
- 16.97B
- Price
- $118.87+1.02% (1D)
- Market cap
- 23.75B
- Price
- $34.72-0.83% (1D)
- Market cap
- 24.97B
- Price
- $13.11-4.06% (1D)
- Market cap
- 10.17B
- Price
- $31.12+1.80% (1D)
- Market cap
- 13.10B
- Price
- $243.36+4.36% (1D)
- Market cap
- 20.96B
- Price
- $527.94-0.10% (1D)
- Market cap
- 22.41B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
72/100 ⭐⭐⭐⭐⭐
- Overall
- -0.1%
- NYSE
- -0.1%
- NASDAQ
- -0.1%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Consumer Defensive | +1.3% | +3.3% | +2.2% | 29.2 | 88/100⭐⭐⭐⭐⭐ |
| Financial Services | -0.1% | +0.8% | +2.0% | 19.2 | 86/100⭐⭐⭐⭐⭐ |
| Communication Services | +0.4% | -1.6% | +2.0% | 22.1 | 74/100⭐⭐⭐⭐⭐ |
| Healthcare | -0.1% | +0.5% | +0.8% | 23.5 | 72/100⭐⭐⭐⭐⭐ |
| Basic Materials | -0.7% | +0.1% | -1.3% | 25.0 | 60/100⭐⭐⭐⭐ |
| Energy | -0.4% | -2.0% | -2.4% | 19.5 | 50/100⭐⭐⭐ |
| Utilities | -1.8% | -0.7% | -5.2% | 27.5 | 37/100⭐⭐ |
| Real Estate | -1.6% | -1.1% | -3.5% | 29.4 | 36/100⭐⭐ |
| Industrials | -0.3% | -0.5% | -10.6% | 30.4 | 22/100⭐ |
| Consumer Cyclical | -0.3% | -2.3% | -6.5% | 43.1 | 17/100⭐ |
| Technology | -1.9% | -4.0% | -9.4% | 41.9 | 7/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.